| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 94.395 | 85.676 | 92.296 | 118.224 | 114.413 | 85.111 | 58.883 | 94.085 | 106.955 | 98.210 |
| Total Income - EUR | 94.676 | 85.679 | 92.297 | 118.500 | 114.525 | 85.219 | 58.906 | 94.189 | 106.983 | 102.540 |
| Total Expenses - EUR | 59.081 | 46.208 | 68.587 | 91.095 | 92.829 | 75.939 | 61.012 | 74.639 | 82.965 | 80.210 |
| Gross Profit/Loss - EUR | 35.595 | 39.471 | 23.711 | 27.405 | 21.695 | 9.281 | -2.106 | 19.550 | 24.018 | 22.330 |
| Net Profit/Loss - EUR | 29.787 | 37.757 | 22.788 | 26.222 | 20.551 | 8.429 | -2.695 | 18.609 | 22.969 | 20.341 |
| Employees | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 3 | 2 | 2 |
Check the financial reports for the company - Epigen Biocomp Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 754 | 585 | 416 | 17.502 | 13.392 | 9.483 | 5.795 | 2.325 | 0 | 30.888 |
| Current Assets | 38.888 | 46.006 | 36.525 | 47.735 | 50.340 | 36.666 | 36.681 | 59.741 | 55.921 | 51.706 |
| Inventories | 5.753 | 2.405 | 1.867 | 6.900 | 2.639 | 6.432 | 1.473 | 0 | 11 | 20 |
| Receivables | 22.040 | 37.842 | 26.688 | 37.640 | 41.398 | 26.555 | 27.225 | 53.273 | 51.527 | 47.486 |
| Cash | 11.096 | 5.760 | 7.970 | 3.195 | 6.303 | 3.679 | 7.983 | 6.468 | 4.384 | 4.199 |
| Shareholders Funds | 30.116 | 37.811 | 22.841 | 26.274 | 20.602 | 23.984 | 10.650 | 18.658 | 23.018 | 20.389 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 9.526 | 8.780 | 14.100 | 39.145 | 43.294 | 22.361 | 31.975 | 43.576 | 33.152 | 58.577 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4.308 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "7210 - 7210" | |||||||||
| CAEN Financial Year |
7211
|
|||||||||
Comments - Epigen Biocomp Srl